134446-26-7

Basic information

• Product Name: Benzenemethanol, a-(4-bromophenyl)-3-methoxy-
• Synonyms: (4-bromophenyl)-(3-methoxyphenyl)-methanol;(4-bromophenyl)(3-methoxyphenyl)methanol;(4-bromophenyl)(3-methoxyphenyl)-methanol
• CAS NO: 134446-26-7
• Molecular Formula: C14H13BrO2
• Molecular Weight: 293.16
• Mol File: 134446-26-7.mol

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, a-(4-bromophenyl)-3-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, a-(4-bromophenyl)-3-methoxy-(134446-26-7)
• EPA Substance Registry System: Benzenemethanol, a-(4-bromophenyl)-3-methoxy-(134446-26-7)

Safety Data

• Hazardous Substances Data: 134446-26-7(Hazardous Substances Data)

Upstream product

• 2845-89-8 1-chloro-3-methoxy-benzene 
• 1122-91-4 4-bromo-benzaldehyde 
• 36282-40-3 (3-methoxyphenyl)magnesium bromide 
• 578-57-4 2-bromoanisole 

Downstream Products

• 1357563-36-0 (3'-chloro-4'-hydroxybiphenyl-4-yl)-(3-hydroxyphenyl)-methanone 
• 1357563-67-7 (3'-chloro-4'-hydroxybiphenyl-4-yl)-(3-methoxyphenyl)-methanone 
• 1357563-35-9 (2'-chloro-4'-hydroxybiphenyl-4-yl)-(3-hydroxyphenyl)-methanone 
• 1357563-65-5 (2'-chloro-4'-methoxybiphenyl-4-yl)-(3-methoxyphenyl)-methanone 
• 1357563-34-8 (3'-fluoro-4'-hydroxybiphenyl-4-yl)-(3-hydroxyphenyl)-methanone 
• 1357563-63-3 (3'-fluoro-4'-methoxybiphenyl-4-yl)-(3-methoxyphenyl)-methanone 
• 1357563-33-7 (4'-hydroxy-3'-methylbiphenyl-4-yl)-(3-hydroxyphenyl)-methanone 
• 1357563-62-2 (4'-methoxy-3'-methylbiphenyl-4-yl)-(3-methoxyphenyl)-methanone 
• 151239-47-3 (4-bromophenyl)-(3-methoxyphenyl)-methanone 
• 134446-27-8 (+/-)-4-Bromo-α-(3-methoxybenzene)benzyl Chloride 

Relevant articles and documents

Expedient Preparation of Aryllithium and Arylzinc Reagents from Aryl Chlorides Using Lithium 4,4′-Di- tert -Butylbiphenylide and Zinc(II) Chloride

We report an efficient method for the preparation of aryllithium and zinc reagents from inexpensive and readily available aryl chlorides by using lithium 4,4′-di-tert-butylbiphenylide (LiDBB) as a lithiation reagent. The resulting organometallic reagents underwent subsequent reactions with a variety of electrophiles, such as an aldehydes, DMF, PhSSO2Ph, TsCN, an aryl halide, or an acid chloride (through Pd-catalyzed cross-coupling). Aryl chlorides bearing substituents, including methoxy, 3,4-methylenedioxy, fluoride, TMS, OTMS, NMe2, acetal, and ketal, were shown to be appropriate substrates. Interestingly, aryl chlorides containing a formyl group could also be used, provided that the formyl group was temporarily converted into an α-amino alkoxide by using the lithium amide of N,N,N′-trimethylethylenediamine (LiTMDA). The presence of a hydroxyl group was also tolerated when it was deprotonated with n-BuLi prior to the addition of LiDBB.

Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis

E2 deficiency in elderly people has directly an effect on the skeleton and can lead to osteoporosis. As 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyses the conversion between active 17β-hydroxysteroid estradiol (E2) and testosterone (T) into their less active 17-ketosteroid and has been found in bones, 17β-HSD2 inhibitor may provide a new approach in the onset of osteoporosis. Bicyclic substituted hydroxyphenylmethanone derivatives were synthesised as steroidomimetics of the substrate E2 and were evaluated for their 17β-HSD2 inhibition and their selectivity toward 17β-HSD1, catalysing the reverse reaction the conversion of estrone (E1) into E2. Highly selective compounds (11, 12, 14, 21 and 22) have been identified, the most promising one (12) showing an IC50 value in the low nanomolar range (101 nM) and a selectivity factor of 13 toward 17β-HSD1. These results make compound 12 an interesting candidate for further biological evaluation.

3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives

The present invention relates to compounds of the formula I, wherein Z1, Z2, X, Q, R1, R2and R3are defined as in the specification, pharmaceutical compositions containing such compounds the use of suc